Biopure continues Phase III trial for Hemopure:
This article was originally published in Clinica
Executive Summary
Biopure is continuing a Phase III clinical trial of its investigational oxygen therapeutic Hemopure, following an independent panel review of safety data from the halfway point of the trial. The single-blind, 640-patient study is evaluating Hemopure, which consists of ultrapurified bovine haemoglobin, as a room temperature-stable, universally compatible alternative to red blood cell transfusion in orthopaedic surgery at more than 40 sites in the US, Canada, Europe and South Africa. The Cambridge, Massachusetts-based company expects to submit the product to the US FDA for market go-ahead this year.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.